{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-23-000032","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2023-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.117521+00:00","generated_at":"2026-06-20T08:28:51.114221+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Centessa gets FDA IND clearance for Phase 1/2a trial of LB101 LockBody candidate for solid tumors","bullets":["FDA cleared IND for LB101, a PD-L1xCD47 bispecific LockBody antibody, for solid tumors.","First LockBody candidate to enter clinic; designed to activate CD47 in tumor microenvironment avoiding systemic toxicity.","CEO Saurabh Saha calls it an important milestone; company plans to advance multiple LockBody candidates.","Phase 1/2a first-in-human trial initiation expected as soon as possible."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-23-000032","json":"https://secwatch.observer/filing/0001847903-23-000032.json","markdown":"https://secwatch.observer/filing/0001847903-23-000032.md","text":"https://secwatch.observer/filing/0001847903-23-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000032/0001847903-23-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000032/cnta-20230126.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T08:28:51.114221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}